TCL Archive Former NIH Director Varmus calls for more oversight of conflicts, expresses surprise at growth of Title 42 program. May 21, 2004Vol.30 No.21
TCL Archive Congressional subcommittee criticizes NIH for lax conflict of interest policies. NIH Director Zerhouni promises change. The subcommittee has asked several NCI officials to testify at another hearing next week. May 14, 2004Vol.30 No.20
TCL Archive Also in this 8-page issue: Intel Chairman Andrew Grove slams NCI director and cancer program for “wishful dreams” and “chemo speeches,” recommends moratorium on funding for cancer research. May 14, 2004Vol.30 No.20
TCL Archive The shadow of Iressa lingered over the FDA Oncologic Drugs Advisory Committee as the panel voted down Genasense (Genta Inc.) and RSR13 (Allos Therapeutics Inc.) at its May 3 meeting. If anyone thought the bar had been lowered for drug approvals, they were mistaken. May 07, 2004Vol.30 No.19
TCL Archive Progression-free survival as a primary endpoint for drug approval requires prospective planning, FDA’s Pazdur says. May 07, 2004Vol.30 No.19
TCL Archive Also in this 8-page issue: NIH Conflict of Interest panel recommends that NIH employees should not receive stock options or equities as compensation for outside work. May 07, 2004Vol.30 No.19
TCL Archive Michelle Le Beau named director of University of Chicago Cancer Research Center. May 07, 2004Vol.30 No.19
